There were 636 press releases posted in the last 24 hours and 162,909 in the last 365 days.

The Scientist Magazine Names NanoString Technologies nCounter Vantage 3D Panels a Top 10 Innovation of 2016

Assay portfolio enables simultaneous analysis of DNA, RNA, and protein for cancer research

SEATTLE, Dec. 01, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its nCounter Vantage 3D™ assays, a portfolio of panels that enable simultaneous analysis of DNA, RNA, and protein were listed by The Scientist as a Top 10 Innovation of 2016. Now in its ninth year, The Scientist top innovation award program recognizes new products revolutionizing life science research.

NanoString announced thirteen nCounter Vantage 3D panels in April 2016 at the American Association for Cancer Research Annual Meeting. This includes seven panels for RNA analysis, two panels for gene fusion analysis, three panels for protein analysis, and the first of three new panels for DNA analysis.  The Vantage 3D™ protein panels can be combined with existing nCounter gene expression panels including the PanCancer panels for simultaneous analysis of RNA and Protein.

“Many areas of life science research, including biomarker discovery and drug development, involve measurements of DNA, RNA, and proteins. Analyzing these different types of biomolecules typically requires three separate platforms. However, the simultaneous digital quantification enabled by our 3D Biology™ approach addresses many of the challenges inherent in sequential testing,” said Joe Beechem, Ph.D., senior vice president of research and development at NanoString Technologies. “Our Vantage 3D assays offer an unprecedented integration of three tests into one experiment. By eliminating the need to divide small samples among different experiments, researchers can extract more data from each precious sample.”

“This year’s crop of Top 10 Innovation submissions contained some great products that posed a real challenge to our panel of experts, tasked by us with singling out the best and brightest,” said Editor-in-Chief Mary Beth Aberlin. “As usual, the independent judges delivered and highlighted innovations that truly have the potential to transform the life sciences.”

/EIN News/ -- For more information about The Scientist’s Top 10 Innovations 2016 and for a full list of winners, visit:

This is the second time in recent years that one of NanoString’s products has been honored as a Top 10 Innovation. In 2013, The Scientist also listed NanoString’s Prosigna® Breast Cancer Prognostic Gene Signature Assay in the Top 10 Innovations list. The Prosigna Assay assesses a patient’s risk of distant breast cancer recurrence at 10 years in postmenopausal women with node-negative (Stage I or II), or node-positive (Stage II), hormone receptor-positive breast cancer by examining the gene expression profile of the patient’s tumor cells.

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,350 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit

The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter, 3D Biology, and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.


Doug Farrell
Vice President, Investor Relations & Corporate Communications
Phone: 206-602-1768

Primary Logo

Distribution channels: Retail